Siemens Healthineers is investing $150 million in new projects to expand production, create jobs and better serve customers in the United States, our largest market globally.

The new investments come on top of the $900 million Siemens Healthineers spends on R&D in the U.S. annually and more than $1 billion invested through facilities expansion, acquisitions and strategic partnerships in the U.S. since 2019.

The latest investments include the following:

• Bringing manufacturing back to the U.S.: relocation of manufacturing operations for Varian, a Siemens Healthineers company, from Baja, Mexico to Palo Alto, CA, adding approximately 50 new manufacturing jobs. The change will reduce the complexity of our global supply chain and improve our ability to respond to demand for Varian’s radiotherapy solutions.
• Strengthening supply-chain resilience: opening mega supply depots in Dayton, NJ and Manteca, CA to increase availability of parts by nearly a third and offer unprecedented delivery flexibility to customers.
• Helping healthcare providers digitize and transform care delivery: construction of a 60,000 square foot Siemens Healthineers Experience Center in Charlotte, NC. The center is part of The Pearl, Charlotte’s research and innovation district.

"North Carolina is home to some of the leading research and innovation firms in the nation,” said North Carolina Governor Josh Stein. “Siemens Healthineers’ $141 million investment in the Pearl in Charlotte is the latest in a long line of companies that see the value of our well-trained workforce thanks to advanced health education programs in our state.”

Added John Kowal, president and head of Siemens Healthineers in the Americas: “Our significant U.S. employee base and broad portfolio of innovations are making vital contributions to the American healthcare system. With these new investments we’re further demonstrating our long-term commitment and desire to grow along with the American economy.”

Other facts about Siemens Healthineers in the U.S.:

• Employs 17,000 people in 18 locations nationwide
• Generates 36% of global revenue
• Global headquarters for Laboratory Diagnostics, Varian, Ultrasound, Molecular Imaging, and PET businesses
• Portfolio includes in vitro and in vivo (imaging) diagnostics, image guided therapy, comprehensive cancer care, digital and AI-driven solutions, technology, workforce and operations consulting
• Strategic partner to many of the nation’s leading healthcare providers